Identification and verification of differentially expressed microRNAs and their target genes for the diagnosis of esophageal cancer

Bioinformatic tools were used to analyze GSE6188, GSE13937 and GSE43732 microarrays, and the top 10 upregulated and downregulated genes of each microarray were identified. It was determined that human microRNA (hsa-miR)-1 and hsa-miR-203 were two downregulated genes in common. Subsequently, it was i...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2018-09, Vol.16 (3), p.3642-3650
Main Authors: Cai, Xiaoyue, Yang, Xiwen, Jin, Changjuan, Li, Lei, Cui, Qing, Guo, Yijun, Dong, Yun, Yang, Xiaohua, Guo, Lili, Zhang, Ming
Format: Article
Language:English
Subjects:
Breast cancer
Care and treatment
Comparative analysis
Computational biology
Diagnosis
Esophageal cancer
Gene expression
Genetic aspects
Health aspects
Health care
Health risk assessment
Medical diagnosis
Medical prognosis
Metastasis
Methods
MicroRNA
MicroRNAs
Mortality
Oncology
Patients
Proteins
Survival analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bioinformatic tools were used to analyze GSE6188, GSE13937 and GSE43732 microarrays, and the top 10 upregulated and downregulated genes of each microarray were identified. It was determined that human microRNA (hsa-miR)-1 and hsa-miR-203 were two downregulated genes in common. Subsequently, it was identified that there were 145 and 335 genes in common targeted by hsa-miR-1 and hsa-miR-203, respectively. In order to narrow the number of target genes down further, the target genes were compared with GSE26886 microarray data. There were five upregulated genes in common with hsa-miR-1, i.e., MMD, BICD1, PTPRG, SDC2 and SEMA6D, and there were eight upregulated genes in common with hsa-miR-203, i.e., PXDN, NRCAM, FMNL2, EIF5A2, GLI3, FSL1, GREM1 and AHR. These genes may become promising biomarkers for the diagnosis of esophageal cancer.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2018.9066